Serum bile acids profiles are altered without change of the gut microbiota composition following a seven-day prednisolone therapy in severe alcoholic hepatitis

References

• Avila MA, Dufour J-F, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, et al. Recent advances in alcohol-related liver disease (ALD): summary of a gut round table meeting. Gut. 2020;69(4):764–17. doi:10.1136/gutjnl-2019-319720.
   PubMed Web of Science ®Google Scholar
• Gougol A, Clemente‐Sanchez A, Argemi J, Bataller R. Alcoholic hepatitis. Clin Liver Disease. 2021;18(2):90. doi:10.1002/cld.1092.
   Google Scholar
• Thursz Mark R, Paul R, Michael A, Andrew A, Megan B, Day Christopher P, Nichola D, Dermot G, Alastair M, Allister G, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–1628. doi:10.1056/NEJMoa1412278.
   PubMed Web of Science ®Google Scholar
• Thursz M, Gual A, Lackner C, Mathurin P, Moreno C, Spahr L, Sterneck M, Cortez-Pinto H. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018;69(1):154–181. doi:10.1016/j.jhep.2018.03.018.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac E, Thevenot T, Piquet M-A, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, et al. Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis. [Internet]. N Engl J Med. 2011 [accessed 2021 May 24];365(19):1781–1789. doi:10.1056/NEJMoa1101214.
   PubMed Web of Science ®Google Scholar
• Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O’Grady JG, Akriviadis E, Sinakos E, Carithers RL, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155(2):458–468.e8. doi:10.1053/j.gastro.2018.05.011.
   PubMed Web of Science ®Google Scholar
• Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie van Leeuwenhoek. 2020;113(12):2019–2040. doi:10.1007/s10482-020-01474-7.
   PubMed Web of Science ®Google Scholar
• Adak A, Khan MR. An insight into gut microbiota and its functionalities. Cell Mol Life Sci. 2019;76(3):473–493. doi:10.1007/s00018-018-2943-4.
   PubMed Web of Science ®Google Scholar
• Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci. 2003;100(18):10452–10459. doi:10.1073/pnas.1734063100.
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65. doi:10.1038/nature08821.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Dbzyxb. 2021;12(5):360–373. doi:10.1007/s13238-020-00814-7.
   Google Scholar
• Shi Q, Dai L, Zhao Q, Zhang X. A review on the effect of gut microbiota on metabolic diseases. Arch Microbiol. 2022;204(3):192. doi:10.1007/s00203-022-02802-3.
   PubMed Web of Science ®Google Scholar
• Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024;1–19. doi:10.1038/s41577-024-01014-8.
   PubMed Web of Science ®Google Scholar
• Collins SL, Stine JG, Bisanz JE, Okafor CD, Patterson AD. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236–247. doi:10.1038/s41579-022-00805-x.
   PubMed Web of Science ®Google Scholar
• Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):140. doi:10.1186/s40168-021-01101-1.
   PubMed Web of Science ®Google Scholar
• Bajaj JS. Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol & Hepatol. 2019;16(4):235–246. doi:10.1038/s41575-018-0099-1.
   PubMed Web of Science ®Google Scholar
• Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505–511. doi:10.1038/s41586-019-1742-x.
   PubMed Web of Science ®Google Scholar
• Zhu L, Wang Y, Pan CQ, Xing H. Gut microbiota in alcohol-related liver disease: pathophysiology and gut-brain cross talk. Front Pharmacol [Internet]. 2023 [accessed 2024 May 30];14. doi:10.3389/fphar.2023.1258062.
   Web of Science ®Google Scholar
• Ciocan D, Rebours V, Voican CS, Wrzosek L, Puchois V, Cassard A-M, Perlemuter G. Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis. Sci Rep. 2018;8(1):4822. doi:10.1038/s41598-018-23146-3.
   PubMedGoogle Scholar
• Kim SS, Eun JW, Cho HJ, Song DS, Kim CW, Kim YS, Lee SW, Kim Y-K, Yang J, Choi J, et al. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. Alimentary Pharmacol & Ther. 2021;53(4):540–551. doi:10.1111/apt.16200.
   PubMed Web of Science ®Google Scholar
• Gao B, Duan Y, Lang S, Barupal D, Wu T-C, Valdiviez L, Roberts B, Choy YY, Shen T, Byram G, et al. Functional microbiomics reveals alterations of the gut microbiome and host Co-metabolism in patients with alcoholic hepatitis. Hepatol Commun. 2020;4(8):1168–1182. doi:10.1002/hep4.1537.
   PubMed Web of Science ®Google Scholar
• Smirnova E, Puri P, Muthiah MD, Daitya K, Brown R, Chalasani N, Liangpunsakul S, Shah VH, Gelow K, Siddiqui MS, et al. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity. Hepatology. 2020;72(1):271–286. doi:10.1002/hep.31178.
   PubMed Web of Science ®Google Scholar
• Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr., et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020;71(2):522–538. doi:10.1002/hep.30832.
   PubMed Web of Science ®Google Scholar
• Sharma A, Roy A, Premkumar M, Duseja A, Taneja S, Grover S, Chopra MM, Dhiman RK. Fecal microbiota transplantation in alcohol-associated acute on chronic liver failure: an open-label clinical trial [internet]. [place unknown]: In Review; 2021 [accessed 2021 May 2] doi:10.21203/rs.3.rs-408638/v1.
   Google Scholar
• Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med [Internet]. 2023 [accessed 2023 Oct 27];19(2):275–293. doi:10.1007/s11739-023-03374-w.
   PubMed Web of Science ®Google Scholar
• Skinner C, Thompson AJ, Thursz MR, Marchesi JR, Vergis N. Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therap Adv Gastroenterol. 2020;13:1756284820942616. doi:10.1177/1756284820942616.
   Web of Science ®Google Scholar
• Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol. 2018;37(3):215–225. doi:10.1007/s12664-018-0859-4.
   PubMedGoogle Scholar
• Pande A, Sharma S, Khillan V, Rastogi A, Arora V, Shasthry SM, Vijayaraghavan R, Jagdish R, Kumar M, Kumar G, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int. 2023;17(1):249–261. doi:10.1007/s12072-022-10438-0.
   PubMed Web of Science ®Google Scholar
• Lieber SR, Rice JP, Lucey MR, Bataller R. Controversies in clinical trials for alcoholic hepatitis. J Hepatol. 2018;68(3):586–592. doi:10.1016/j.jhep.2017.09.013.
   PubMed Web of Science ®Google Scholar
• Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn’s disease. Gut. 1983;24(3):182–186. doi:10.1136/gut.24.3.182.
   PubMed Web of Science ®Google Scholar
• Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356(6344):aag2770. doi:10.1126/science.aag2770.
   Web of Science ®Google Scholar
• Lindell AE, Zimmermann-Kogadeeva M, Patil KR. Multimodal interactions of drugs, natural compounds and pollutants with the gut microbiota. Nat Rev Microbiol. 2022;20(7):431–443. doi:10.1038/s41579-022-00681-5.
   PubMed Web of Science ®Google Scholar
• Ramayanam NR, Mahalingam VT, Amarnath RN, Mohan VK. Influence of pharmacokinetics in responders and non-responders of prednisolone based therapy in alcoholic hepatitis patients. J Pharm Negat Results. 2022; 363–371. doi:10.47750/pnr.2022.13.S01.45.
   Web of Science ®Google Scholar
• Shukla PK, Meena AS, Pierre JF, Rao R. Central role of intestinal epithelial glucocorticoid receptor in alcohol- and corticosterone-induced gut permeability and systemic response. Faseb J. 2022;36(1):e22061. doi:10.1096/fj.202101424R.
   PubMed Web of Science ®Google Scholar
• Zhang J, Feng D, Law H-W, Wu Y, Zhu G, Huang W, Kang Y. Integrative analysis of gut microbiota and fecal metabolites in rats after prednisone treatment. Microbiol Spectr. 2021;9(3):e00650–21. doi:10.1128/Spectrum.00650-21.
   PubMed Web of Science ®Google Scholar
• Cuffaro B, Assohoun ALW, Boutillier D, Peucelle V, Desramaut J, Boudebbouze S, Croyal M, Waligora-Dupriet A-J, Rhimi M, Grangette C, et al. Identification of new potential biotherapeutics from human gut microbiota-derived bacteria. Microorganisms. 2021;9(3):565. doi:10.3390/microorganisms9030565.
   PubMed Web of Science ®Google Scholar
• Lallement J, Raho I, Merlen G, Rainteau D, Croyal M, Schiffano M, Kassis N, Doignon I, Soty M, Lachkar F, et al. Hepatic deletion of serine palmitoyl transferase 2 impairs ceramide/sphingomyelin balance, bile acids homeostasis and leads to liver damage in mice. Biochim et Biophys Acta (BBA) - Mol Cell Biol Lipids. 2023;1868(8):159333. doi:10.1016/j.bbalip.2023.159333.
   PubMed Web of Science ®Google Scholar
• Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17(1):10–12. doi:10.14806/ej.17.1.200.
   Google Scholar
• Benson G. Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acids Res. 1999;27(2):573–580. doi:10.1093/nar/27.2.573.
   PubMed Web of Science ®Google Scholar
• Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–359. doi:10.1038/nmeth.1923.
   PubMed Web of Science ®Google Scholar
• Blanco-Míguez A, Beghini F, Cumbo F, McIver LJ, Thompson KN, Zolfo M, Manghi P, Dubois L, Huang KD, Thomas AM, et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol. 2023;41(11):1633–1644. doi:10.1038/s41587-023-01688-w.
   PubMed Web of Science ®Google Scholar
• McMurdie PJ, Holmes S, Watson M. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLOS ONE. 2013;8(4):e61217. doi:10.1371/journal.pone.0061217.
   PubMed Web of Science ®Google Scholar
• Oksanen J, Simpson G, Blanchet F, Kindt R, Legendre P, Minchin P, O’Hara R, Solymos P, Stevens M, Szoecs E, et al. Electron injection in metal assisted chemical etching as a fundamental mechanism for electroless electricity generation. J Phys Chem Lett. 2022;13(24):5648–5653. doi:10.1021/acs.jpclett.2c01302.
   PubMed Web of Science ®Google Scholar
• Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, Tickle TL, Weingart G, Ren B, Schwager EH, et al. Multivariable association discovery in population-scale meta-omics studies. PLOS Comput Biol. 2021;17(11):e1009442. doi:10.1371/journal.pcbi.1009442.
   PubMed Web of Science ®Google Scholar
• Harnisch L-O, Mihaylov D, Bein T, Apfelbacher C, Moerer O, Quintel M. A reduced glycine-to-taurine ratio of conjugated serum bile acids signifies an adaptive mechanism and is an early marker of outcome in acute respiratory distress syndrome. Intern Emerg Med. 2023;18(2):607–615. doi:10.1007/s11739-022-03152-0.
   PubMedGoogle Scholar
• Sugita T, Amano K, Nakano M, Masubuchi N, Sugihara M, Matsuura T. Analysis of the serum bile acid composition for differential diagnosis in patients with liver disease. Gastroenterol Res Pract. 2015;2015:717431. doi:10.1155/2015/717431.
   PubMed Web of Science ®Google Scholar
• Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4(2):bvz039. doi:10.1210/jendso/bvz039.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F, Sambhara S. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLOS ONE. 2013;8(1):e54600. doi:10.1371/journal.pone.0054600.
   PubMed Web of Science ®Google Scholar
• Asada M, Oishi E, Sakata S, Hata J, Yoshida D, Honda T, Furuta Y, Shibata M, Suzuki K, Watanabe H, et al. Serum lipopolysaccharide-binding protein levels and the incidence of cardiovascular disease in a general Japanese population: the hisayama study. J Am Heart Assoc. 2019;8(21):e013628. doi:10.1161/JAHA.119.013628.
   PubMed Web of Science ®Google Scholar
• Schumann RR, Kirschning CJ, Unbehaun A, Aberle H, Knopf H-P, Lamping N, Ulevitch RJ, Herrmann F. The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT-3 and other cytokine-inducible nuclear proteins. Mol Cellular Biol [Internet]. 1996 [accessed 2024 Jan 18];16(7):3490–3503. doi:10.1128/MCB.16.7.3490.
   PubMed Web of Science ®Google Scholar
• Wan Y, Freeswick PD, Khemlani LS, Kispert PH, Wang SC, Su GL, Billiar TR. Role of lipopolysaccharide (LPS), interleukin-1, interleukin-6, tumor necrosis factor, and dexamethasone in regulation of LPS-binding protein expression in normal hepatocytes and hepatocytes from LPS-treated rats. Infect Immun. 1995;63(7):2435–2442. doi:10.1128/iai.63.7.2435-2442.1995.
   PubMed Web of Science ®Google Scholar
• Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018;69(2):396–405. doi:10.1016/j.jhep.2018.03.031.
   PubMed Web of Science ®Google Scholar
• Muthiah MD, Smirnova E, Puri P, Chalasani N, Shah VH, Kiani C, Taylor S, Mirshahi F, Sanyal AJ. Development of alcohol‐associated hepatitis is associated with specific changes in gut‐modified bile acids. Hepatol Commun. 2022;6(5):1073. doi:10.1002/hep4.1885.
   PubMed Web of Science ®Google Scholar